NRG-BN013: PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED SRS (FSRS) FOR INTACT BRAIN METASTASES NRG-BN013: PHASE III TRIAL OF SINGLE FRACTION STEREOTACTIC RADIOSURGERY (SRS) VERSUS FRACTIONATED SRS (FSRS) FOR INTACT BRAIN METASTASES NRG-BN013 is an unblinded, randomized phase III trial to determine if the time to local failure is significantlylonger with FSRS compared to SRS in patients with intact brain metastasis.NCT06500455Eva Galvan MD

Phase III Randomized Study Testing Non-inferiority of Short-course Ultra-hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) For Stage II-IIIB, Extremity, Resectable Soft Tissue SarcomaPhase III Randomized Study Testing Non-inferiority of Short-course Ultra-hypofractionated Radiation (UHRT-5) Versus Standard Fractionation (RT-25) For Stage II-IIIB, Extremity, Resectable Soft Tissue SarcomaWe propose a clinical trial comparing standard radiation (RT-25) to ultra-hypofractionated radiation (UHRT-5). If negative, this trial would stop participants from being treated, as many are, with an inferior regimen. If positive, this trial would establish a new standard of careClinicalTrials.gov registration not requiredEva Galvan MD

MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer MONITOR-Breast: Monitoring cell-free tumor DNA as a marker of recurrence in Breast Cancer This is a prospective, observational study designed to evaluate the clinical validity of Myriad Genetics’ MRD test in patients diagnosed with breast cancer. It is expected that enrollment will be split between the different breast cancer subtypes defined by immunohistochemistry (HR+/HER2-, HER2+ (HR+ and HR-), TNBC) and according to BINV-A of National Comprehensive Cancer Network guidelines with ER+ status used here as >10% of nuclei staining.ClinicalTrials.gov registration not requiredMarcela Mazo Canola MD